A proton pump inhibitor is an acid-suppressing drug that inhibits the gastric hydrogen–potassium ATPase in the secretory membrane of stomach parietal cells [1]. This ATP-driven pump exchanges intracellular protons for luminal potassium and performs the terminal step in gastric acid secretion [1][2]. Conventional proton pump inhibitors, including omeprazole and related substituted benzimidazoles, are administered as prodrugs [3][4]. Their weakly basic structures favor accumulation in the acidic secretory canaliculi, where protonation promotes conversion into reactive species. These activated compounds form covalent bonds with accessible cysteine residues of the pump, suppressing its proton-transport activity. Acid inhibition can therefore persist after the circulating parent compound has been cleared, with recovery involving restoration of functional pumps [1][3]. The pharmacological class is distinct from potassium-competitive acid blockers, which inhibit the same transporter through a different binding mechanism [2]. Its characteristic combination of acid-associated activation and covalent pump modification connects the chemical properties of the prodrug to prolonged suppression of gastric acid secretion [3][4].